SCHEMBL295418

SCHEMBL295418

O=C1N=NN(c2ccccc2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.45
MGLL Q99685 1/20 0.41
KMT2A Q03164 7/20 0.41
ALDH1A1 P00352 6/20 0.41
MEN1 O00255 5/20 0.41
MAPT P10636 5/20 0.41
LOX P28300 2/20 0.41
TDP1 Q9NUW8 3/20 0.40
KDM4E B2RXH2 2/20 0.40
CYP1A2 P05177 1/20 0.40
CHRM2 P08172 1/20 0.40
CYP3A4 P08684 1/20 0.40
CHRM1 P11229 1/20 0.40
TSHR P16473 1/20 0.40
PTGS1 P23219 1/20 0.40
DRD3 P35462 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LOXL3 P58215 1/20 0.39
LOXL4 Q96JB6 1/20 0.39
LOXL2 Q9Y4K0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263572 0.67 CYP1A2 (0.47) GAAKMT2AALDH1A1MEN1MAPT
SCHEMBL6735947 0.65 KMT2A (0.41) GAAMGLLKMT2AALDH1A1MEN1
SCHEMBL8871184 0.65 GAA (0.45) GAAMGLLKMT2AALDH1A1MEN1
SCHEMBL4282424 0.64 MEN1 (0.47) GAAKMT2AALDH1A1MEN1MAPT
SCHEMBL1722780 0.63 GSK3B (0.71) GAAMGLLKMT2AALDH1A1MEN1
SCHEMBL10134037 0.63 KMT2A (0.39) GAAMGLLKMT2AALDH1A1MEN1
SCHEMBL12291974 0.63 MAPT (0.64) GAAKMT2AALDH1A1MEN1MAPT
SCHEMBL16280099 0.63 MGLL (0.62) GAAMGLLKMT2AALDH1A1MEN1
SCHEMBL6731372 0.63 KMT2A (0.64) GAAKMT2AALDH1A1MEN1MAPT
SCHEMBL447260 0.62 GAA (1.00) GAAMGLLKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130143916-A1 COMPOUND LIBRARIES MADE THROUGH PHOSPHINE-CATALYZED ANNULATION/TEBBE/DIELS-ALDER REACTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-06-06 US claimed
EP-0778023-B1 Product comprising rapamycin or particular derivatives and an NMDA or AMPA antagonist for use for the treatment of epilepsy or Huntington's Disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or Huntington's Disease. WYETH CORP (US) 2003-03-12 EP claimed
EP-1002535-A1 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2000-05-24 EP claimed
EP-0778023-A1 Neuroprotective agents AMERICAN HOME PRODUCTS CORPORATION (US) 1997-06-11 EP claimed
US-4252719-A REMOVAL OF A TERTIARY HYDROGEN FROM A 5-A-STEROID BY CHLORINATING THE STEROID BEING FIRST ESTERIFIED BY AN IODOARYL-CONTAINING ESTERIFICATION AGENT RESEARCH CORPORATION (US) 1981-02-24 US claimed
JP-9183727-A None JP disclosed
EP-4312851-B1 MECHANOCHROMIC PRESSURE SENSOR FOR SAFE AND EFFECTIVE TISSUE HANDLING IN MINIMALLY INVASIVE SURGERY FONDAZIONE ST ITALIANO TECNOLOGIA (IT) 2024-10-09 EP disclosed
US-20240180576-A1 MECHANOCHROMIC PRESSURE SENSOR FOR SAFE AND EFFECTIVE TISSUE HANDLING IN MINIMALLY INVASIVE SURGERY FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2024-06-06 US disclosed
WO-2022201024-A1 MECHANOCHROMIC PRESSURE SENSOR FOR SAFE AND EFFECTIVE TISSUE HANDLING IN MINIMALLY INVASIVE SURGERY FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2022-09-29 WO disclosed
US-10160766-B1 Benzopyranyl tetracycle compound and pharmaceutical composition having excellent anti-inflammatory effect comprising the same SPARK BIOPHARMA, INC. (KR) 2018-12-25 US disclosed
EP-0968223-B1 BIOCONJUGATION OF MACROMOLECULES SIGMA ALDRICH CO LLC (US) 2016-12-21 EP disclosed
EP-2256133-B1 Bioconjugation of macromolecules SIGMA ALDRICH CO LLC (US) 2016-12-14 EP disclosed
EP-0778023-A1 Neuroprotective agents AMERICAN HOME PRODUCTS CORPORATION (US) 1997-06-11 EP disclosed
EP-0778023-A1 Neuroprotective agents AMERICAN HOME PRODUCTS CORPORATION (US) 1997-06-11 EP disclosed
EP-0710110-A1 RAPAMYCIN CONJUGATES AND ANTIBODIES ABBOTT LABORATORIES (US) 1996-05-08 EP disclosed
EP-0676471-A2 Effector proteins of rapamycin AMERICAN HOME PRODUCTS CORPORATION (US) 1995-10-11 EP disclosed
WO-1994025022-A1 RAPAMYCIN CONJUGATES AND ANTIBODIES ABBOTT LABORATORIES (US) 1994-11-10 WO disclosed
WO-1994025072-A1 RAPAMYCIN CONJUGATES AND ANTIBODIES AMERICAN HOME PRODUCTS CORPORATION (US) 1994-11-10 WO disclosed
US-4396750-A Process for synthesizing silylated polyalkenamers THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 1983-08-02 US disclosed
US-4252719-A REMOVAL OF A TERTIARY HYDROGEN FROM A 5-A-STEROID BY CHLORINATING THE STEROID BEING FIRST ESTERIFIED BY AN IODOARYL-CONTAINING ESTERIFICATION AGENT RESEARCH CORPORATION (US) 1981-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160766-B1 Benzopyranyl tetracycle compound and pharmaceutical composition having excellent anti-inflammatory effect comprising the same HMGB1, HMGB2, HMGB3 GAA 3006/4885MGLL 4789/4885KMT2A 3284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.